Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SDHB | P21912 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440927 | 0.90 | LMNA (0.52) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440982 | 0.87 | KIT (0.44) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440963 | 0.87 | KIT (0.43) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3441223 | 0.85 | GRIN1 (0.44) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440926 | 0.85 | PTGS2 (0.47) | KITLMNAALDH1A1TDP1 | |
| SCHEMBL3440886 | 0.84 | KIT (0.44) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440956 | 0.83 | KIT (0.47) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440884 | 0.82 | KIT (0.43) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3441009 | 0.82 | KIT (0.43) | GRIN1GRIN2BKITLMNAALDH1A1 | |
| SCHEMBL3440922 | 0.82 | KIT (0.44) | GRIN1GRIN2BKITLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | claimed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | claimed |
| EP-2229385-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | claimed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | claimed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | claimed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2229385-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FBP1, ALDOA, GCK | GRIN1 4429/4885GRIN2B 4723/4885KIT 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.